Table 3.
Pretreatment | Posttreatment | Changes | P | |
---|---|---|---|---|
Clinical characteristics | ||||
n (men/women) | 20 (17/3) | |||
Age (years) | 37.4 ± 8.9 | |||
Weight (kg) | 69.8 ± 6.2 | 64.9 ± 4.4 | -4.9 (-6.1, -3.7) | <0.001∗∗ |
BMI (kg/m2) | 27.6 ± 0.4 | 25.7 ± 0.7 | -1.9 (-2.3, -1.5) | <0.001∗∗ |
Waist circumference (cm) | 91.0 ± 4.1 | 85.0 ± 2.7 | -6.1 (-7.2, -4.9) | <0.001∗∗ |
Biochemical and metabolic parameters | ||||
FBG (mmol/L) | 9.9 ± 2.8 | 6.3 ± 1.1 | -3.3 (-5.1, -2.0) | <0.001∗∗ |
2 hPBG (mmol/L) | 16.5 ± 5.5 | 7.8 ± 1.6 | -8.7 (-11.4, -5.9) | <0.001∗∗ |
FINS (μU/ml) | 15.6 ± 7.2 | 14.7 ± 6.5 | -0.9 (-4.6, 2.9) | 0.636 |
HOMA-IR | 6.7 ± 2.9 | 4.9 ± 2.1 | -1.7 (-3.2, -0.24) | 0.024∗ |
HbA1c (%) | 10.0 ± 2.0 | 6.2 ± 0.6 | -3.8 (-4.7, -2.9) | <0.001∗∗ |
TCH (mmol/L) | 5.9 ± 1.4 | 5.1 ± 1.3 | -0.8 (-1.5, -0.1) | 0.028∗ |
HDL (mmol/L) | 0.9 ± 0.1 | 1.0 ± 0.2 | 0.1 (-0.1, 0.1) | 0.172 |
LDL (mmol/L) | 3.2 ± 1.3 | 3.2 ± 1.1 | 0.0 (-0.4, 0.5) | 0.862 |
TG (mmol/L) | 3.8 ± 3.6 | 2.1 ± 1.0 | -1.7 (-3.3, -0.2) | 0.030∗ |
ALT (U/L) | 56.4 ± 35.4 | 32.4 ± 23.1 | -24.1 (-34.4, -13.7) | <0.001∗∗ |
AST (U/L) | 38.3 ± 18.7 | 23.0 ± 7.9 | -15.3 (-23.3, -7.3) | <0.001 |
ALP (U/L) | 77.7 ± 24.7 | 68.8 ± 21.6 | -8.9 (-18.4, 0.5) | 0.062 |
GGT (U/L) | 79.1 ± 69.1 | 46.8 ± 26.2 | -32.4 (-59.1, -5.6) | 0.020∗ |
FGF21 (pg/ml) | 159.6 ± 35.7 | 124.2 ± 27.8 | -110.7 (-185.8, -35.6) | 0.006∗∗ |
Liver fat content (%) | 19.3 ± 9.4 | 10.6 ± 6.3 | -8.7 (-11.9, -5.5) | <0.001∗∗ |
Abbreviations: BMI: body mass index; FBG: fasting blood glucose; 2 hPBG: 2-hour postprandial blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; LDL: low-density lipoprotein cholesterol; ALT: alanine amino transferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: γ-glutamyl transferase; FGF21: fibroblast growth factor 21. ∗P < 0.05; ∗∗P < 0.01.